Fungal Infection Clinical Trial
Official title:
A Pilot Study to Evaluate the Appropriateness of the Voriconazole Dosing Regimen Based on the Population Pharmacokinetic Model and the Influence of Sex on the Pharmacokinetics of Voriconazole
Verified date | November 2018 |
Source | Seoul National University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A pilot study was performed to evaluate the appropriateness of the voriconazole dosing regimen based on the population pharmacokinetic model and the influence of sex on the pharmacokinetics of voriconazole
Status | Completed |
Enrollment | 11 |
Est. completion date | October 28, 2018 |
Est. primary completion date | October 28, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 20 Years to 45 Years |
Eligibility |
Inclusion Criteria: - Those who have been informed of the nature of the trial and have voluntarily agreed to participate in this study and have signed an IRB approved consent before all screening tests - Healthy Korean male and female volunteers aged 20 to 45 - Those with a body weight of 50 kg or more and less than 90 kg and a body mass index (BMI) of 18 or more and less than 27 (BMI(kg/m2) = body weight (kg)/{height(m)}2 - CYP2C19 EM or PM Exclusion Criteria: - Subjects with clinical evidence of significant respiratory, circulatory, renal, hepatic, endocrine, blood, neuropsychiatric, skeletal or other chronic diseases, alcohol or drug addiction - Subjects with a history of gastrointestinal disorders (Crohn's disease, ulcers, acute or chronic pancreatitis, etc.) or gastrointestinal surgery (excluding simple cecal surgery or hernia surgery) that may affect the absorption of the test drug - Those with a history of substance abuse within the last 2 months - Those who have taken any prescribed medicines or herbal medicines within 2 weeks prior to the date of the first medicines, or those taking any general medicines (OTC) or vitamin preparations (eligible if the other conditions are reasonable according to the judgment of the investigator) - Those who donate blood within 30 days before the date of the first dose or who have participated in the clinical study of other clinical trial drugs or marketed drugs within 3 months - Those who have had significant adverse reactions such as hypersensitivity reactions to azole drugs including drugs for clinical research - Those who are not planning on or planning to have a pregnancy during the trial and are not able to use a recognized method of contraception (eg, sterilization surgery of the person and partner, intrauterine contraceptive device, or diaphragm contraception (such as diaphragm or condom use) - Persons who are continuously drinking (21 units / week, 1 unit = 10 g of pure alcohol) or who can not abstain from 3 days before the first dose to the end of the clinical trial - Those who smoked more than 10 cigarettes per day for the last 3 months or who can not quit smoking 3 days before the first dose - Those who consume grapefruit / caffeine-containing food within 3 days of the first dose or who cannot be prohibited during the clinical study period - Screening tests for urine pregnancy (ß-hCG) positive or lactating women - Those with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption. - A person who is found to be unsuitable for participation in clinical research due to safety laboratory results or other reasons |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Seoul National University Hospital Clinical Trial Center | Seoul |
Lead Sponsor | Collaborator |
---|---|
Seoul National University Hospital |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Peak plasma concentration (Cmax) | Pharmacokinetic sampling after administration of drugs from day 1 to day 7 | Day 1 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours, Day 5 12 hours, Day 6 0, 12 hours, Day 7 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours | |
Primary | Area under the plasma concentration versus time curve from the time of dosing to the last measurable concentration (AUClast) | Pharmacokinetic sampling after administration of drugs from day 1 to day 7 | Day 1 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours, Day 5 12 hours, Day 6 0, 12 hours, Day 7 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours | |
Secondary | Genetic polymorphisms of CYP2C9 and CYP3A4 | Exploratory evaluation | Day 1 0 hour | |
Secondary | Hepatic safety marker of miRNA-122 | Exploratory safety evaluation | Day 1 0 hour, Day 5 12 hour, Day 7 12 hour | |
Secondary | Safety and tolerability evaluation by monitoring adverse events (number of subjects and cases) | Safety and tolerability evaluation | Day 1 to Day 12 | |
Secondary | Physical examination (list of current medications) | Safety and tolerability evaluation | Day 1 to Day 12 | |
Secondary | Physical examination (list of any symptoms or pain) | Safety and tolerability evaluation | Day 1 to Day 12 | |
Secondary | Physical examination (Medical and surgical history) | Safety and tolerability evaluation | Day 1 to Day 12 | |
Secondary | Evaluation of Vital signs (body temperature °C) | Safety and tolerability evaluation | Day 1 to Day 12 | |
Secondary | Evaluation of Vital signs (blood pressure mmHg) | Safety and tolerability evaluation | Day 1 to Day 12 | |
Secondary | Evaluation of Vital signs (pulse (heart rate, beats per minute)) | Safety and tolerability evaluation | Day 1 to Day 12 | |
Secondary | Evaluation of Vital signs (breathing rate (respiratory rate, beats per minute)) | Safety and tolerability evaluation | Day 1 to Day 12 | |
Secondary | Safety and tolerability evaluation by 12-lead ECG (P wave, PR interval, QRS complex, J-point, ST segment, T wave, Corrected QT interval, U wave) | Safety and tolerability evaluation | Day 1 to Day 12 | |
Secondary | number of participants with abnormal laboratory values (hematologic, chemical, urine) | Safety and tolerability evaluation | Day 1 to Day 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03641131 -
Ampholipad Real-World Data in Taiwan
|
||
Not yet recruiting |
NCT03292224 -
Systemic Fungal Infections in ICU Patients
|
N/A | |
Completed |
NCT01371656 -
Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation
|
Phase 3 | |
Completed |
NCT00936117 -
Pharmacokinetics of Posaconazole Prophylaxis in Acute Leukemia
|
Phase 2 | |
Completed |
NCT00740389 -
TMC125-TiDP2-C187: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Interaction Between TMC125 and Two Antifungal Agents (Fluconazole and Voriconazole), All at Steady-state in Healthy Subjects.
|
Phase 1 | |
Completed |
NCT03857399 -
Empiric Therapy of Patients With Persistent Fever and Agranulocytosis Using Caspofungin
|
Phase 2 | |
Not yet recruiting |
NCT04215458 -
Microbiota in Skin and Mucosa of Patients With Inflammatory Skin Diseases
|
N/A | |
Completed |
NCT03667690 -
Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis
|
Phase 3 | |
Completed |
NCT02957929 -
Safety, Pharmacokinetics, Bioavailability, Food Effect, Drug-Drug Interaction Study of APX001 Administered Orally
|
Phase 1 | |
Completed |
NCT01419678 -
Pharmacokinetic Analysis of Posaconazole in Lung Transplant Recipients
|
N/A | |
Recruiting |
NCT00333645 -
Prophylaxis With Caspofungin in High-Risk Liver Transplantation
|
Phase 2 | |
Not yet recruiting |
NCT03650439 -
Fungal Infections in Patients With Hematological Malignancies
|
||
Completed |
NCT01303549 -
Anidulafungin vs Amphotericin B Safety in High Risk Hepatic Transplant Recipients
|
Phase 4 | |
Completed |
NCT00811642 -
Posaconazole Treatment of Invasive Fungal Infection (IFI) (P05551)
|
Phase 3 | |
Withdrawn |
NCT00430469 -
Safety of hLF1-11 for the Treatment of Infectious Complications Among HSCT Recipients
|
Phase 1/Phase 2 | |
Terminated |
NCT00386997 -
ProphyALL - Study on the Safety of Liposomal Amphotericin B to Prevent Antifungal Infections in Elderly Patients With Acute Lymphoblastic Leukemia
|
Phase 4 | |
Completed |
NCT00514358 -
Fluconazole Pharmacokinetics in Infants
|
Phase 1 | |
Completed |
NCT04166669 -
A Drug-Drug Interaction Study of CYP3A4 Inhibition and Pan-CYP Induction on APX001
|
Phase 1 | |
Recruiting |
NCT05150327 -
Multicenter Cohort Study of Invasive Fungal Filamentous Fungal Infections in Liver Transplant Patients
|
||
Completed |
NCT02387983 -
Pharmacokinetics and Safety of Oral Posaconazole (MK-5592)Tablets in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-117)
|
Phase 1 |